Scarica l'app Stockscreener
5.945
10.20%
-0.675
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$6.62
Aprire:
$6.62
Volume 24 ore:
38.54M
Relative Volume:
1.51
Capitalizzazione di mercato:
$5.86B
Reddito:
$1.31M
Utile/perdita netta:
$-597.65M
Rapporto P/E:
-6.1289
EPS:
-0.97
Flusso di cassa netto:
$-425.62M
1 W Prestazione:
-1.74%
1M Prestazione:
+110.82%
6M Prestazione:
+110.82%
1 anno Prestazione:
+79.07%
Intervallo 1D:
$5.94
$7.30
Intervallo di 1 settimana:
$5.8201
$7.30
Portata 52W:
$1.83
$8.28
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
5.945 | 6.52B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio stock drops 10% Friday, then pops after hours as IBRX heads into a holiday break - Bez Kabli
IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU - Stocktwits
ImmunityBio (NASDAQ:IBRX) Trading Down 10.1%Time to Sell? - MarketBeat
Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More - Benzinga
ImmunityBio Stock Faces Uncertainty Amid Market Volatility - timothysykes.com
ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX) - MarketBeat
Is ImmunityBio Inc Gaining or Losing Market Support? - Benzinga
Will ImmunityBio Inc. outperform tech stocksRate Cut & AI Driven Price Predictions - mfd.ru
ImmunityBio (NASDAQ:IBRX) Stock Price Up 1.2%What's Next? - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
Behind the Scenes of ImmunityBio's Latest Options Trends - Benzinga
A Look At ImmunityBio (IBRX) Valuation After ASCO 2026 Spotlight And Anktiva Growth Momentum - Yahoo Finance
Is It Too Late To Consider ImmunityBio (IBRX) After The Recent 181% Monthly Surge? - Yahoo Finance
ImmunityBio Advances Chemotherapy Free Lymphoma Regimen As Global Anktiva Story Grows - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Trading Down 5.3%Here's Why - MarketBeat
ImmunityBio (IBRX) jumps ahead of oncology event - MSN
ImmunityBio (IBRX) Jumps Ahead of Oncology Event - Finviz
ImmunityBio Shares Gain Momentum on Strong Sales and Regulatory Progress - AD HOC NEWS
ImmunityBio's Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC) - openPR.com
ImmunityBio stock steadies near $7 after 15% jump; earnings next up - TechStock²
ImmunityBio, Inc. (IBRX) Investor Outlook: Analyzing the 70% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
ImmunityBio (NASDAQ:IBRX) Trading 14.5% HigherHere's What Happened - MarketBeat
ImmunityBio Surge After Saudi Approvals and FDA Meeting - Hoodline
ImmunityBio’s Stock Soars on Promising Trial Results and Strategic Advances - StocksToTrade
New Sign-Off Propels ImmunityBio - Los Angeles Business Journal
ImmunityBio rally causes $492M paper losses for short sellers - MSN
Did ImmunityBio’s (IBRX) New Chemotherapy‑Free CAR‑NK Phase 2 Trial Just Redefine Its Investment Narrative? - Sahm
Aug Ideas: Does ImmunityBio Inc have a competitive edgeOil Prices & Weekly Setup with ROI Potential - baoquankhu1.vn
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Shares Up 7.3%Still a Buy? - MarketBeat
ImmunityBio initiates another cell therapy trial with no chemotherapy needs - MSN
ImmunityBio (NASDAQ:IBRX) Trading Down 4.1%What's Next? - MarketBeat
ImmunityBio Accelerates Pipeline with New Lymphoma Trial Amid Stellar Revenue Forecast - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Stock Price Down 7.1%What's Next? - MarketBeat
Soon-Shiong, ImmunityBio Exit Challenge to Cancer Drug Financing - Bloomberg Law News
ImmunityBio extends gains after FDA views on Anktiva label expansion - MSN
ImmunityBio Stockholder Targets Soon-Shiong In Chancery - Law360
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.3%Should You Buy? - MarketBeat
Soon-Shiong Defends ImmunityBio Financing Pact for Cancer Drug - Bloomberg Law News
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients - MSN
ImmunityBio Shares Maintain Upward Momentum on Clinical and Commercial Progress - AD HOC NEWS
ImmunityBio Stock Maintains Momentum with New Clinical Trial - AD HOC NEWS
ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy By Investing.com - Investing.com Nigeria
ImmunityBio (NASDAQ:IBRX) Trading Down 1.9%Should You Sell? - MarketBeat
Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs - Stocktwits
Piper Sandler see label expansion potential for ImmunityBio, Inc. (IBRX)’s Anktiva following Quilt data - MSN
Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data - Yahoo Finance
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas - BioSpace
ImmunityBio Launches Phase 2 Study of Cell Therapy in Indolent Lymphomas - marketscreener.com
ImmunityBio launches phase 2 chemotherapy-free car-nk cell therapy trial with Anktiva - marketscreener.com
ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy - Investing.com
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunitybio Inc Azioni (IBRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sachs David C. | Chief Financial Officer |
Feb 10 '26 |
Option Exercise |
0.00 |
82,236 |
0 |
322,818 |
| LAUER REGAN J | Chief Accounting Officer |
Feb 10 '26 |
Option Exercise |
0.00 |
5,482 |
0 |
115,740 |
| Adcock Richard | CEO & President |
Feb 10 '26 |
Option Exercise |
0.00 |
274,122 |
0 |
625,513 |
| Simon Barry J. | Director |
Jan 20 '26 |
Sale |
7.20 |
151,967 |
1,094,297 |
3,091,604 |
| Selecky Christobel | Director |
Jan 16 '26 |
Option Exercise |
2.98 |
50,000 |
149,000 |
50,000 |
| Selecky Christobel | Director |
Jan 20 '26 |
Option Exercise |
2.98 |
25,000 |
74,500 |
25,000 |
| Selecky Christobel | Director |
Jan 16 '26 |
Sale |
5.00 |
50,000 |
250,000 |
0 |
| Selecky Christobel | Director |
Jan 20 '26 |
Sale |
7.51 |
25,000 |
187,650 |
0 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):